AU2023219232A1 - Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine - Google Patents

Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine Download PDF

Info

Publication number
AU2023219232A1
AU2023219232A1 AU2023219232A AU2023219232A AU2023219232A1 AU 2023219232 A1 AU2023219232 A1 AU 2023219232A1 AU 2023219232 A AU2023219232 A AU 2023219232A AU 2023219232 A AU2023219232 A AU 2023219232A AU 2023219232 A1 AU2023219232 A1 AU 2023219232A1
Authority
AU
Australia
Prior art keywords
combination
pharmaceutical combination
arginine
sildenafil
pde5 inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023219232A
Other languages
English (en)
Inventor
Ming Wei Chao
Po Tung Chen
Chin Hung Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Future Pharmtech Inc
Original Assignee
Future Pharmtech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Future Pharmtech Inc filed Critical Future Pharmtech Inc
Publication of AU2023219232A1 publication Critical patent/AU2023219232A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023219232A 2022-02-09 2023-02-09 Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine Pending AU2023219232A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TW111104639A TWI859506B (zh) 2022-02-09 2022-02-09 化合物組合用於製作血管疾病治療藥的用途
TW111104639 2022-02-09
PCT/GB2023/050296 WO2023152500A1 (en) 2022-02-09 2023-02-09 Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine

Publications (1)

Publication Number Publication Date
AU2023219232A1 true AU2023219232A1 (en) 2024-07-25

Family

ID=85283927

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023219232A Pending AU2023219232A1 (en) 2022-02-09 2023-02-09 Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine

Country Status (8)

Country Link
US (1) US20250134892A1 (cg-RX-API-DMAC10.html)
EP (1) EP4475833A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025504219A (cg-RX-API-DMAC10.html)
KR (1) KR20240146018A (cg-RX-API-DMAC10.html)
CN (1) CN116808224A (cg-RX-API-DMAC10.html)
AU (1) AU2023219232A1 (cg-RX-API-DMAC10.html)
TW (1) TWI859506B (cg-RX-API-DMAC10.html)
WO (1) WO2023152500A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI879058B (zh) * 2023-08-31 2025-04-01 未來新藥股份有限公司 Pde5抑制劑組合於促進神經突生長之新穎用途
CN122055146A (zh) * 2023-08-31 2026-05-15 未来新药股份有限公司 Pde5抑制剂组合于促进神经突生长的新颖用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4699299A (en) 1998-06-26 2000-01-17 Nutracorp Scientific, Inc. Promoting nitric oxide and cyclic gmp activity
IL132460A0 (en) * 1999-10-19 2001-03-19 Laniado Shlomo Sildenafil preparation

Also Published As

Publication number Publication date
CN116808224A (zh) 2023-09-29
US20250134892A1 (en) 2025-05-01
TW202332450A (zh) 2023-08-16
EP4475833A1 (en) 2024-12-18
KR20240146018A (ko) 2024-10-07
WO2023152500A1 (en) 2023-08-17
JP2025504219A (ja) 2025-02-06
TWI859506B (zh) 2024-10-21

Similar Documents

Publication Publication Date Title
Guo et al. Anti-fibrotic effects of puerarin on CCl4-induced hepatic fibrosis in rats possibly through the regulation of PPAR-γ expression and inhibition of PI3K/Akt pathway
WO2002003996A1 (en) Use of dammarane-type tritepenoid saporins
JP4411414B2 (ja) 糖尿病性神経障害の治療に対する組成物及びその方法
US20250134892A1 (en) Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine
US9289401B2 (en) Nutritional supplements
CN112654264A (zh) 使用至少一种甘氨酸或其衍生物、至少一种n-乙酰半胱氨酸或其衍生物和至少一种烟酰胺核糖核苷或nad+前体的组合物和方法
RU2014101261A (ru) Системы, способы и составы для лечения рака
Fuentes et al. Protection against indomethacin-induced loss of intestinal epithelial barrier function by a quercetin oxidation metabolite present in onion peel: In vitro and in vivo studies
KR100516827B1 (ko) 일산화질소생산억제제
KR101516677B1 (ko) 지방성 간 질환의 치료용 의약 조성물
WO2021230146A1 (ja) Nr及び/又はnmnとセサミン類とを含有する組成物
KR19980070878A (ko) 새로운 진통제 조성물
WO2025026900A1 (en) Compounds for the treatment or prevention of gout
US20210128596A1 (en) Compositions and methods for treating septic cardiomyopathy
JP2024016228A (ja) アセトアミノフェン(apap)によって引き起こされる毒性を予防、低減または根絶するための方法および組成物
JP2022550312A (ja) Fxrアゴニストの使用を含む処置
US20250009692A1 (en) Micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
TWI451866B (zh) 治療及預防患者因心肌缺血所引起的不適的醫藥組合物
KR20250098567A (ko) 한속단 추출물을 유효성분으로 포함하는 신경병증성 통증 예방 또는 치료용 약학 조성물
JP4896531B2 (ja) 血中CoQ10量を増加させる医薬組成物
CN101756984B (zh) 吡咯并喹啉醌在治疗和预防动脉粥样硬化中的应用
AU2023225518A1 (en) Chromanol compounds for treatment or prophylaxis of ageing-associated disorders
HK40089668A (en) Composition containing sesamin or like and nr and/or nmn
BR112021002855B1 (pt) Usos de pelo menos uma glicina ou de um derivado da mesma, de pelo menos uma n-acetilcisteína ou de um derivado da mesma e de pelo menos um ribosídeo de nicotinamida ou de um precursor de nad+ , composições compreendendo os mesmos, e kit
HK40050780A (en) Compositions and methods using at least one glycine or derivative thereof, at least one n-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or nad+ precursor